NASDAQ:IPHA

Innate Pharma - IPHA Stock Forecast, Price & News

$2.00

-0.07 (-3.38%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.98
▼
$2.10
50-Day Range: $2.00
▼
$3.20
52-Week Range: $1.98
▼
$6.50

Volume: 14,822 shs
Average Volume: 12,293 shs
Market Capitalization: $159.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.15

Innate Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 357.5% Upside
$9.15 Price Target
Short Interest: Bearish
0.14% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.88
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.42) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

923rd out of 1,095 stocks

Biological Products, Except Diagnostic Industry

150th out of 171 stocks

3.4

Analyst's Opinion

Consensus Rating
Innate Pharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.15, Innate Pharma has a forecasted upside of 357.5% from its current price of $2.00.
Amount of Analyst Coverage
Innate Pharma has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.14% of the outstanding shares of Innate Pharma have been sold short.
Short Interest Ratio / Days to Cover
Innate Pharma has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Innate Pharma has recently increased by 2.29%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Innate Pharma does not currently pay a dividend.
Dividend Growth
Innate Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPHA.

3.3

News and Social Media Coverage

News Sentiment
Innate Pharma has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Innate Pharma this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innate Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.20% of the stock of Innate Pharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Innate Pharma are expected to decrease in the coming year, from ($0.42) to ($0.80) per share.
Price to Book Value per Share Ratio
Innate Pharma has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Innate Pharma (NASDAQ:IPHA) Stock

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Stock News Headlines

September 23, 2022 | markets.businessinsider.com

Innate : Data From Phase 2 Trial Of Lacutamab In Advanced Mycosis Fungoides Shows Clinical Activity

September 23, 2022 | seekingalpha.com

Innate says lacutamab shows response in blood/skin cancer patients in phase 2 trial

September 15, 2022 | finanznachrichten.de

Innate Pharma SA: Innate Pharma Reports First Half 2022 Financial Results and Business Update

September 15, 2022 | markets.businessinsider.com

Innate Pharma Turns To Profit In H1

September 5, 2022 | finance.yahoo.com

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

August 1, 2022 | seekingalpha.com

Hot Stocks: BA jumps on Dreamliner news, HSBC gains on earnings, PSO also rises 10%, while IPHA sinks

August 1, 2022 | finance.yahoo.com

AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer

August 1, 2022 | seekingalpha.com

Innate stock slumps 16% as AstraZeneca pulls plug on monalizumab in head/neck cancer after trial failure

July 21, 2022 | markets.businessinsider.com

Innate Pharma: Sanofi To Progress IPH6401/SAR'514 Into Development; Triggers Milestone Payment

June 23, 2022 | finance.yahoo.com

Innate Pharma to Participate in Upcoming Investor Conference

June 3, 2022 | markets.businessinsider.com

Innate Pharma : Anti-CD39 Monoclonal Antibody IPH5201 Advances To Phase 2 Study In Lung Cancer

May 20, 2022 | finance.yahoo.com

Outcome of Innate Pharma’s 2022 Annual General Meeting

May 10, 2022 | seekingalpha.com

Innate Pharma reports Q1 results

May 3, 2022 | apnews.com

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

May 3, 2022 | finance.yahoo.com

Innate Pharma Establishes an At-The-Market ("ATM") Program on Nasdaq

May 3, 2022 | finance.yahoo.com

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

April 5, 2022 | finance.yahoo.com

Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F

March 25, 2022 | seekingalpha.com

Innate Pharma GAAP EPS of -€0.66, revenue of €24.7M

March 24, 2022 | finanznachrichten.de

Innate Pharma SA: Innate Pharma Reports Full Year 2021 Financial Results and Business Update

March 18, 2022 | finanznachrichten.de

Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

March 3, 2022 | finance.yahoo.com

Number of Shares and Voting Rights of Innate Pharma as of March 1, 2022

February 15, 2022 | finance.yahoo.com

Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022

January 29, 2022 | nasdaq.com

Innate Pharma S.A. ADS (IPHA)

January 5, 2022 | nasdaq.com

Innate Pharma Secures EUR 28.7 Mln Non-Dilutive Financing - Quick Facts

December 16, 2021 | markets.businessinsider.com

Innate : First Patient Dosed In IPH6101/SAR443579 Phase 1/2 Trial In Various Blood Cancers

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Company Calendar

Today: 10/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IPHA
CUSIP: N/A
CIK: 1598599
Web: www.innate-pharma.com
Phone: 33-4-30-30-30-30
Fax: N/A
Employees: 215
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.15
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $3.10
Forecasted Upside/Downside: +357.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 2.34
Quick Ratio: 1.73

Sales & Book Value

Annual Sales: $29.23 million
Price / Sales: 5.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.60 per share
Price / Book: 1.25

Miscellaneous

Outstanding Shares: 79,730,000
Free Float: 54,303,000
Market Cap: $159.46 million
Optionable: Not Optionable
Beta: 0.56

Key Executives

Dr. Mondher Mahjoubi M.D. (Age 64)
Chairman of Exec. Board & CEO
Comp: $1.03M

Mr. Yannis Morel Ph.D. (Age 49)
Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
Comp: $408.78k

Dr. Herve Brailly (Age 61)
Co-Founder & Chairman of Supervisory Board

Dr. François Romagné Ph.D. (Age 58)
Founder

Mr. Eric Vivier D.V.M. (Age 58)
M.B.A., Ph.D., Founder, Sr. VP & Chief Scientific Officer

Dr. Marc Bonneville Ph.D. (Age 62)
Founder

Mr. Jean Jacques Fournié Ph.D.
Founder

Mr. Alessandro Moretta M.D.
Ph.D., Founder

Mr. Frederic Lombard M.B.A. (Age 47)
Sr. VP & CFO

Ms. Odile Belzunce (Age 42)
VP of Compliance & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IPHA Stock - Frequently Asked Questions

Should I buy or sell Innate Pharma stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPHA shares.
View IPHA analyst ratings or view top-rated stocks.
What is Innate Pharma's stock price forecast for 2022?: 4 brokerages have issued 12 month price targets for Innate Pharma's stock. Their IPHA share price forecasts range from $3.10 to $12.00. On average, they anticipate the company's share price to reach $9.15 in the next twelve months. This suggests a possible upside of 357.5% from the stock's current price.
View analysts price targets for IPHA or view top-rated stocks among Wall Street analysts.
How have IPHA shares performed in 2022?: Innate Pharma's stock was trading at $4.56 at the beginning of 2022. Since then, IPHA stock has decreased by 56.1% and is now trading at $2.00.
View the best growth stocks for 2022 here.
What is Hervé Brailly's approval rating as Innate Pharma's CEO?: 4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Innate Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and Sanofi (SNY).

When did Innate Pharma IPO?: (IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.
What is Innate Pharma's stock symbol?: Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."
How do I buy shares of Innate Pharma?: Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Innate Pharma's stock price today?: One share of IPHA stock can currently be purchased for approximately $2.00.
How much money does Innate Pharma make?: Innate Pharma (NASDAQ:IPHA) has a market capitalization of $159.46 million and generates $29.23 million in revenue each year.
How many employees does Innate Pharma have?: The company employs 215 workers across the globe.
How can I contact Innate Pharma?: Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The official website for the company is www.innate-pharma.com. The company can be reached via phone at 33-4-30-30-30-30 or via email at investors@innate-pharma.com.

This page (NASDAQ:IPHA) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Innate Pharma - IPHA Stock Forecast, Price & News

Innate Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month